A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's...

Area of Science:

• Gastroenterology
• Immunology
• Medical Technology

Background:

• Activated granulocytes and monocytes are implicated in Crohn's disease (CD) pathogenesis.
• Previous small studies suggested granulocyte/monocyte apheresis (GMA) may benefit CD patients.
• A need exists to validate GMA efficacy in a rigorous clinical trial.

Purpose of the Study:

• To compare the efficacy of granulocyte/monocyte apheresis (GMA) against a sham procedure.
• To evaluate GMA's effectiveness in achieving clinical remission in moderate to severe Crohn's disease.
• To assess treatment outcomes in a randomized, double-blind study design.

Main Methods:

• A randomized, double-blind study comparing GMA with sham apheresis.
• Inclusion of patients with active Crohn's disease (CDAI 220-450).
• Ten apheresis sessions over 9 weeks, with efficacy assessed at week 12.

Main Results:

• No significant difference in clinical remission rates between GMA (17.8%) and sham (19.2%) groups.
• Similar clinical response rates observed in both GMA (28.0%) and sham (26.9%) groups.
• No significant differences in CDAI scores, quality of life, or endoscopic scores between groups.

Conclusions:

• Granulocyte/monocyte apheresis (GMA) was well-tolerated by patients.
• The study did not demonstrate GMA's superiority over sham procedures for Crohn's disease.
• Further research may be needed to explore potential roles or alternative applications of GMA.